Baird Medical's MWA Technology Successfully Applied in Endocrine Procedures

PR Newswire03-31

NEW YORK, March 31, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") proudly announces the successful utilization of its advanced microwave...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523949986?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523949986","market":"us","top_or_hot":-1,"title":"Baird Medical's MWA Technology Successfully Applied in Endocrine Procedures","media":"PR Newswire","content":"<div>\n<p>NEW YORK, March 31, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\") proudly announces the successful utilization of its advanced microwave...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medicals-mwa-technology-successfully-applied-in-endocrine-procedures-302415245.html?tc=eml_cleartime\">Source Link</a>\n\n</div>\n","source":"lsy1612503552367","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baird Medical's MWA Technology Successfully Applied in Endocrine Procedures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaird Medical's MWA Technology Successfully Applied in Endocrine Procedures\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-31 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.prnewswire.com/news-releases/baird-medicals-mwa-technology-successfully-applied-in-endocrine-procedures-302415245.html?tc=eml_cleartime><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, March 31, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\") proudly announces the successful utilization of its advanced microwave...</p>\n\n<a href=\"https://www.prnewswire.com/news-releases/baird-medicals-mwa-technology-successfully-applied-in-endocrine-procedures-302415245.html?tc=eml_cleartime\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MWA","symbol_name":"Mueller Water Products","start_time":0,"source_url":"https://www.prnewswire.com/news-releases/baird-medicals-mwa-technology-successfully-applied-in-endocrine-procedures-302415245.html?tc=eml_cleartime","article_id":"2523949986","we_media_id":null,"thumbnails":[],"rights":{"source":"lsy1612503552367","url":"https://www.prnewswire.com/news-releases/baird-medicals-mwa-technology-successfully-applied-in-endocrine-procedures-302415245.html?tc=eml_cleartime","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2523949986","pubTimestamp":1743424200,"columns":[],"sourceInfo":{"source_id":"lsy1612503552367","name":"PR Newswire"},"weMediaInfo":null,"summary":"NEW YORK, March 31, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd.   proudly announces the successful utilization of its advanced microwave ablation  technology in two recent endocrine procedures . These procedures were performed by Dr. Saka Kazeem, MD, a distinguished endocrinologist with over 30 years of clinical experience.Using Baird Medical's MWA system for the first time, Dr. Kazeem praised its efficiency and seamless integration into clinical practice. \"The system is both intuitive and optimizes procedure time, allowing treatments more streamlined without compromising patient outcomes,\" he stated.Baird Medical remains dedicated to driving innovation in medical technology and promoting the adoption of MWA among healthcare professionals worldwide. \"Dr. Kazeem's successful experience highlights the value of our technology in improving clinical workflows and patient care,\" said Haimei Wu, Chairwoman of Baird Medical. \"We are excited to introduce our solutions to more ph","collect":0,"end_time":0,"defaultTopTitle":"prnewswire.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MWA":"Mueller Water Products","LU1721427968.SGD":"BNP PARIBAS AQUA \"CRH\" (SGDHDG) INC","BDMD":"百德医疗","BK4082":"医疗保健设备","BK4161":"工业机械","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","BDMDW":"BAIRD MEDICAL INVESTMENT HLDGS LTD C/WTS 01/10/2029 (TO PUR COM)","LU1543694498.USD":"法巴水资源基金RH MD Dis"},"translate_title":"Baird Medical的MWA技术成功应用于内分泌手术","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDMD":1,"MWA":1,"BDMDW":0.9},"content_text":"NEW YORK, March 31, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\") proudly announces the successful utilization of its advanced microwave ablation (MWA) technology in two recent endocrine procedures . These procedures were performed by Dr. Saka Kazeem, MD, a distinguished endocrinologist with over 30 years of clinical experience.Dr. Saka Kazeem and MWAUsing Baird Medical's MWA system for the first time, Dr. Kazeem praised its efficiency and seamless integration into clinical practice. \"The system is both intuitive and optimizes procedure time, allowing treatments more streamlined without compromising patient outcomes,\" he stated.Baird Medical remains dedicated to driving innovation in medical technology and promoting the adoption of MWA among healthcare professionals worldwide. \"Dr. Kazeem's successful experience highlights the value of our technology in improving clinical workflows and patient care,\" said Haimei Wu, Chairwoman of Baird Medical. \"We are excited to introduce our solutions to more physicians seeking effective, minimally invasive treatment options.\"As the Company continues to expand its presence, Baird Medical is committed to collaborating with leading medical professionals and institutions to drive further innovation in microwave ablation technology and its applications.About Baird MedicalBaird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as \"may\", \"could\", \"should\", \"expect\", \"intend\", \"might\", \"will\", \"estimate\", \"anticipate\", \"believe\", \"budget\", \"forecast\", \"intend\", \"plan\", \"potential\", \"predict\", \"potential\" or \"continue\", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled \"Risk Factors\" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523949986","isCrawlerRequest":true}